Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...

Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, ...

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.

Siddharth Mittal, MD and CEO of Biocon said the company will launch Liraglutide in Europe in FY26 along with its partner, ...

Dasatinib is prescribed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults.

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...